Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

Chinese-American Bio/Pharmaceutical Society Presents: 2021 BioPacific Conference

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster is a proud long-term platinum sponsor of the the Chinese-American Bio/Pharmaceutical Society and its annual BioPacific Conference. This is the flagship event to bring scientists, executives, and biopharmaceutical professionals from

Morrison & Foerster is a proud long-term platinum sponsor of the Chinese-American Bio/Pharmaceutical Society and its annual BioPacific Conference. This is the flagship event to bring scientists, executives, and biopharmaceutical professionals from the Pacific Rim countries together to discuss the latest advances in the world of life sciences, the unprecedented challenges and promises facing the industry, and the breathtaking developments and opportunities in Asia/Pacific countries.Partners Janet Xiao and Chuck Comey will participate in an engaging virtual panel conversation on IP Considerations and Investment trends for Life Sciences.In addition, FDA partner Bethany Hills will lead a breakout room discussion with associate KB Do addressing Effective Use of Science in the FDA Regulatory Process.<h5>11:20 A.M. – 12:00 P.M.</h5>Panel Discussion 1: IP Considerations and Investment trends for Life Sciences This session will cover intellectual property considerations for life science transactions and stories of investment in new technologies. Options to structure a new company will be discussed. Moderator: Janet Xiao, PhD, JD, Partner, Head of MoFo’s China Life Sciences, Morrison & Foerster LLP Panelists: Chuck Comey, Partner, Morrison & Foerster LLP Sean Cao, PhD, MBA, Managing Director, the CBC Group Neil Desai, PhD, Founder & CEO, AADI <h5>12:00 P.M. – 12:30 P.M.</h5>Breakout room talks Room 1: Effective Use of Science in the FDA Regulatory Process Bethany Hills, PhD, Partner, Morrison & Foerster LLP Keunbong (KB) Do, Associate, Morrison & Foerster LLPView the conference <a href="http://www.biopacificconference.org/" target="_blank">website</a>.<hr>

Chinese-American Bio/Pharmaceutical Society Presents: 2021 BioPacific Conference

Sign Up

Described by a client as “a real superstar able to handle even the most complex and important transactions” (Chambers), Chuck advises on mergers and acquisitions, venture capital and private equity financings, and joint ventures and strategic alliances in the technology, consumer and life sciences sectors. His practice experience includes working on the ground in China and Japan for 16 years.Chuck is ranked Band 1 by Chambers USA for California Corporate/M&A: Deals in Asia. He has also been recommended as a leading lawyer for M&A by Chambers Global since 2015, earning the distinction of “Expertise Based Abroad” for his work in China. Clients in Chambers describe Chuck as: “a go-to attorney in the market for complex, cross-border transactions involving China” and “our go-to on CFIUS and China issues.”Beginning in 1994, Chuck was seconded by Morrison Foerster to the legal department of a major Japanese trading company, and thereafter was resident for nine years in Morrison Foerster’s Tokyo office, where he specialized in cross-border mergers and acquisitions and strategic alliances. Before relocating to Silicon Valley in July 2010, Chuck opened and served as managing partner of the firm’s Shanghai office from 2003 – 2010. He reads and speaks Mandarin.Chuck is admitted to practice in California and is a member of the California and American bar associations.

柯弥（Charles Comey）律师被客户称为“能够处理最为复杂且重要的交易的超级明星律师”（《钱伯斯指南》），他就技术、消费品及生命科学行业的并购、风险投资和私募股权融资、合资企业和战略性联盟事宜向客户提供法律咨询。他的执业经验包括在中国和日本实地工作长达16年。自2015年起，柯弥律师连续被《钱伯斯全球指南》推荐为并购业务领域的领先律师，并因其在中国的工作被评为“驻海外专家”。在《钱伯斯全球指南》中，客户将柯弥律师评价为“涉及中国的复杂跨境交易的首选律师”和“我们关于CFIUS和中国事宜的首选律师”。自1994年起，柯弥律师由美富借调至日本一家大型贸易公司的法律部，其后九年他在美富东京办事处工作，专注于处理跨境并购和策略性联盟。柯弥律师建立了美富上海办公室，并于2003年至2010年担任该办公室的管理合伙人，他于2010年7月调派至硅谷。柯弥律师拥有中文阅读与会话能力。柯弥律师是加利福尼亚州执业律师，也是加利福尼亚州和美国律师公会的会员。

Charles C. Comey

Senior Counsel

Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet’s clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals.Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients’ complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. As impressed clients noted to Chambers, “Janet’s work is thorough, polished and always of the highest caliber. She is well equipped to advise international clients on patent prosecution and strategy in the biotech industry, drawing on substantial technical knowledge.”Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She helps some of the world’s most-sophisticated biopharmaceutical companies and investors assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works regularly with patent litigators in the event of legal challenges by third-party competitors or vice versa, and she is frequently called upon to represent clients in litigation and post-grant proceedings.Janet is the Head of firm’s China Life Sciences Group and served as co-chair of the global Life Sciences Group from 2016 to 2019. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Chambers Global praises her as an outstanding IP lawyer “who is renowned for her work on IP issues concerning complex cross-border transactions, where she regularly advises Chinese clients.” In a recent edition of Chambers Global, a client says, “Janet . . . is very experienced in advising life sciences clients doing business in China and the US . . . She is highly responsive and always gives practical advice. Her IP expertise adds tremendous value to our business.”Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Biopharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term. She is also a member of BayHelix, a nonprofit organization of Chinese heritage leaders in the global life sciences and healthcare fields.

肖荐（Janet Xiao）博士的业务侧重于为生命科学公司处理在全球范围内的专利采购、专利组合管理和战略策划事宜。肖博士服务的客户范围广泛，包括大型跨国生物制药公司，例如赛尔基因公司（Celgene）和基因泰克公司（Genentech），也包括全球范围的新兴创业公司。她经常就与各种技术有关的专利事宜向客户提供法律意见，其中涉及的技术包括抗体疗法、细胞疗法、纳米医学、基因疗法、给药系统、诊断和和营养学等。来自全球的创新者纷纷向肖博士寻求专利申请和专利战略的法律咨询，这一点也得到了《钱伯斯指南》的认可。她帮助客户开发和加强其复杂的专利组合，从而为客户实现最大的商业价值。在为制药行业的客户制定数十亿美元专利组合的战略方面，肖博士发挥着重要的作用。《钱伯斯指南》曾引用客户评价称，“肖博士是我曾合作过的律师当中知识最渊博、效率最高的一位律师。她能很好地将专利组合的历史信息用于全球专利申请问题上。”肖博士针对风险投资、技术交易、并购和生物医药产品的市场推广与生产许可事宜开展广泛的知识产权尽职调查审查工作。她协助世界上一些最成功的生物制药公司和投资者，为其产品开发和投资评估潜在风险，并制定先发制人的风险管理策略。她曾牵头处理过数百个知识产权尽职调查项目，并凭借自己对癌症免疫治疗、基因编辑、新一代测序、液体活检、抗体制造和医疗设备领域的专利方面的深厚知识而闻名。肖博士时常与专利诉讼律师合作，处理由第三方竞争者提出的法律质疑，或对第三方竞争者提出的法律质疑，她还经常受聘代表客户处理专利诉讼和授予后程序。肖博士是美富中国生命科学业务组主管，她曾在2016至2019期间担任美富全球生命科学业务组的联席主管。肖博士是全球为数不多的既拥有很强的全球战略性知识产权管理技能，同时又对中国和中国客户独特的知识产权问题具有深刻理解的知识产权律师之一，她一直是处理中美跨境交易和在中国境内经营中所涉知识产权问题的首选律师。《钱伯斯全球指南》称赞她是一位优秀的知识产权律师，“她因处理与复杂跨境交易有关的知识产权问题工作而知名，经常代表中国客户处理这方面的事宜” 。在近期一版《钱伯斯全球指南》中，某客户评价称，“肖博士在为于中国和美国开展业务的生命科学客户提供法律意见方面，有非常丰富的经验。她非常负责而且总是提供切实可行的法律意见。她在知识产权方面的专业意见为我们的业务增添了巨大价值。”自2005年以来，肖博士一直积极参与北美华人生物医药协会（CABS）的领导工作。该协会是一家非营利组织，致力于成为连接中美两国生命科学领域的纽带。肖博士在2011至2012年间担任该协会主席。她还是百华协会（BayHelix）的成员。百华协会是一家非营利组织，由全球生命科技和医疗保健产业领域的华人精英组成。

Janet Xiao

Partner

Keunbong (KB) Do leverages his industry experience and Ph.D. in biophysical chemistry to assist clients with patent prosecution strategy and U.S. Food & Drug Administration (FDA) regulatory matters, representing pharmaceutical, device, biotech, and food companies. KB provides exceptional science-based advocacy to clients in both patent and regulatory matters.He is experienced in strategically drafting patent applications, prosecuting, and managing patent portfolios in the U.S. and internationally, and conducting intellectual property due diligence including patentability and freedom-to-operate assessments.He also counsels clients on FDA regulatory matters related to drugs, devices, and biological products, including preparation of marketing submissions, clinical study design, exclusivity, current good manufacturing practice (CGMP), promotion, and other post-market regulatory issues including product recall. Particularly, he has extensive experience counseling on in vitro diagnostics (IVD) regulation, including matters related to analytical and clinical study design, CGMP, premarket submissions, FDA meetings, and labeling.KB received his J.D. from Harvard Law School. At Harvard, he received an Irving Oberman Memorial Prize for his paper on intellectual property. Prior to law school, KB worked at Samsung SDI as a leader of the Chemical-Mechanical Planarization (CMP) slurry development team and as a senior research engineer in the semiconductor materials development group.He earned his Ph.D. in biophysical chemistry from Stanford University, where he was a John Stauffer Stanford Graduate Fellow and a Korea Foundation for Advanced Studies Fellow. His research focused on characterizing and engineering fluorescent proteins using various concepts and tools in molecular biology, biochemistry, and physical chemistry.KB received his B.S., summa cum laude, in chemistry from Seoul National University. He was also a Sergeant in the Republic of Korea Army.He is admitted to practice in California and New York and is a fluent Korean speaker.

Keunbong (KB) Do

Associate

Life Sciences + Healthcare

Emerging Companies + Venture Capital

Mergers + Acquisitions

IP Due Diligence

Patent Strategy + Prosecution

Venture Intellectual Property

FDA + Healthcare Regulatory and Compliance

Chinese-American Bio/Pharmaceutical Society Presents: 2021 BioPacific Conference - 575504851

Chinese-American Bio/Pharmaceutical Society Presents: 2021 BioPacific Conference

30 Oct 2021 8:30 AM - 5:00 PM PDT

11:20 A.M. – 12:00 P.M.

12:00 P.M. – 12:30 P.M.